<DOC>
	<DOCNO>NCT00001579</DOCNO>
	<brief_summary>This dose escalation study . During first period study , initial pharmacological assessment fluorouracil administer intravenously along oral leucovorin calcium make . Leucovorin calcium give orally bid day 1-3 . Fluorouracil give 24 hour infusion day 2 . After 2 week rest period resolution toxicity experience first period treatment , patient give escalate dose fluorouracil fix dose leucovorin calcium ethynyluracil . Ethynyluracil leucovorin calcium give bid orally day 1-3 week . Fluorouracil give bid orally day 2 week . Treatment repeat three week follow one week rest period . 3 6 patient enrol dose level . Dose escalation proceeds maximum tolerate dose ( MTD ) determine . MTD define dose precede 2 patient experience dose limit toxicity .</brief_summary>
	<brief_title>A Phase I Trial 5-Fluorouracil Given With 776C85 ( GW776 ) Low-Dose Leucovorin Adult Patients With Solid Tumors</brief_title>
	<detailed_description>The primary purpose Phase I protocol develop orally administer regimen fluorouracil ( 5-FU ) give fix dos leucovorin ( LV ) 776C85 ( GW776 ) , mechanism-based inhibitor dihydropyrimidine dehydrogenase ( DPD ) , rate-limiting enzyme involve catabolism 5-FU . In presence 776C85 , 5-FU clear renal mechanism . The schedule employ intend mimic pharmacologic profile associate 24 hour weekly continuous infusion 5-FU without need indwell central venous catheter . The target population adult cancer patient solid tumor . The first week , patient receive single dose 5-FU give 24 hour continuous IV infusion recommend Phase II dose low-dose oral LV . In third week , patient begin 776C85 ( GW776 ) LV PO day 1 , 2 , 3 fixed dos . Oral 5-FU give day 2 , dose escalate successive cohort patient . Treatment repeat weekly three week , follow one week break . The dose 5-FU adjusted accord individual tolerance . Cohorts three patient enter dose level 5-FU , escalate dose-limiting toxicity see ( guideline outline follow schema ) . Treatment continue indefinitely evidence disease progression , provide patient tolerate therapy wish continue . Biochemical monitoring suggest profound sustain inhibition DPD single dose 20 mg PO 776C85 day 1-3 week three four week . Once MTD define daily dose day 1 , 2 , 3 schedule , simplify schedule evaluate single dose 776C85 day 1 evening , oral leucovorin day 1 2 , 5-FU give day 2 single dose . Since pharmaceutical company decide go combined tablet eniluracil/5-FU future study , new schedule oral leucovorin day 1 &amp; 2 , 776C85 5-FU give day 2 single dose .</detailed_description>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor fail standard therapy therapy exists . Tumor may locally advance unresectable , recurrent and/or metastatic . Lymphomas minimal involvement bone marrow also eligible . No primary malignancy metastatic disease CNS . No symptomatic preexist peripheral neuropathy . PRIOR/CURRENT THERAPY : BIOLOGIC THERAPY : No immunotherapy within past 4 week . Recovered toxic effect . CHEMOTHERAPY : No chemotherapy within past 4 week ( 6 week nitrosoureas ) . No mitomycin within past 12 week . Recovered toxic effect . ENDOCRINE THERAPY : Not specify . RADIOTHERAPY : No radiotherapy within past 2 week ( 8 week strontium therapy ) . Recovered toxic effect . SURGERY : Recovered prior surgery . OTHER : No concurrent cimetidine . PATIENT CHARACTERISTICS : AGE : 18 . PERFORMANCE STATUS : ECOG 02 . LIFE EXPECTANCY : Not specify . HEMATOPOIETIC : Absolute granulocyte count least 2000/mm ( 3 ) ; Platelet count least 100,000/mm ( 3 ) . HEPATIC : Bilirubin great 2 time upper normal limit ; SGOT/SGPT great 4 time upper normal limit . RENAL : Creatinine great 1.6 mg/dL ; Creatinine clearance great 55 mL/min . OTHER : Not pregnant nursing . Fertile patient must use effective contraception . Not HIV positive . No active infection require intravenous antibiotic therapy . No serious concurrent illness . No evidence hemolytic uremic syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>Biochemical Modulation</keyword>
	<keyword>Dihydropyrimidine Dehydrogenase</keyword>
	<keyword>Oral Administration</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>